Released: 08/18/2023 Expires: 09/30/2024 (subject to change)
CE for this activity will not be available after this date.
Webinar Date and Time:9/14/2023 from 1:30-3:00 PM CT OnDemand Viewing Now Available! Overview Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and affects an estimated 25% of the adult population in the US. About one-quarter of patients with NAFLD have nonalcoholic steatohepatitis (NASH). Nurse practitioners are key providers for this population and need to stay abreast of best practices for screening, diagnosis, and treatment of these conditions. In this presentation, NP experts Drs. Kelly Casler and Amanda Chaney will discuss screening, diagnosis and management of NASH with you. They will also share details of the exciting emerging treatment options with you and the brand-new nomenclature.
Identify patients who are candidates for NAFLD screening based on established risk factors.
Summarize strategies for the diagnosis and risk stratification of NASH.
Choose evidence-based recommendations for the management of NASH, using both nonpharmacologic and pharmacologic approaches.
Describe the mechanism of action, safety, and efficacy of emerging liver-directed pharmacotherapies for the management of NASH.
Disclosure This program was planned in accordance with AANP CE Standards and Policies.
Kelly Casler has no relevant financial relationships to disclose.
Amanda Chaney has the following disclosures:
Presenter/consultant for APEA and PESI in the area of liver disease and GI.
Author for Springer in the area of liver disease.
All Planners involved in this activity have no relevant financial relationships to disclose.
This program is supported by independent medical educational grants from Madrigal Pharmaceuticals and Novo Nordisk Inc.
Disclaimer Individuals who have contributed to the CE Center were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
CE Credit Instructions
Read this activity description, including objectives and disclosures.
Complete the Pretest associated to the activity. (Note: you must complete the pre-test in order to be able to view the recording of the webinar.)
Complete the educational content completely:
Webinar Presentation: Attend the live webinar or watch the recorded on-demand video of the webinar.
Review all additional materials provided (handouts, post-test reviews, any other downloadable resources).
After completing all content, click on the blue Next Steps button:
Complete the post-test.
Submit the evaluation to receive full AANP CE/Rx credit.
Additional Information For questions or more information concerning this online CE opportunity contact the AANP CE Support team at CECenter@aanp.org.
1.25 Contact Hour(s) of CE, 0.25 of which may be applied towards Pharmacology